<DOC>
	<DOCNO>NCT00280111</DOCNO>
	<brief_summary>It observe child get severe rotavirus infection , subsequent infection cause either symptom generally mild moderate diarrhea . This evidence basis develop vaccine since suggests first infection immunize child disease upon re-infection . It find neonatal avirulent strain 116E I321 induce protective immunity offer clinical protection least one year . Both strain well characterize safety study do animal model . These candidate vaccine strain evaluate safety immunogenicity adult child ( 2 12 year age ) randomize double blind placebo control trial Cincinnati , USA . In India , diversity rotavirus strain great great prevalence malnutrition co-infection enteric pathogen . These vaccine therefore , also test India .</brief_summary>
	<brief_title>Safety Immunogenicity Study Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E I321 Infants</brief_title>
	<detailed_description>This study phase I randomize , double blind , safety immunogenicity study live , attenuated neonatal rotavirus vaccine candidate strain 116E I321 healthy non-malnourished infant age 8-12 week . Informed , write , witnessed consent obtain parent infant screen 6 week age . Infants ( n=90 ) randomize ( 30 per group ) receive one dose either 116E I321 vaccine ( 10^5 fluorescence focus unit , FFu ) placebo 8 week age . The rotavirus vaccine administer different time DPT ( Diptheria-Pertussis-Tetanus ) , OPV ( Oral Polio Vaccine ) HBV ( Hepatitis B vaccine ) immunization since trial represent first safety study infant strain . The DPT , OPV HBV vaccine give regular EPI schedule 6 , 10 14 week precaution technique routinely place . The test article administer orally two week first DPT , OPV HBV dose , half hour administer 2.5 ml bicarbonate buffer stomach acidity . Evaluation reactogenicity consist daily recording symptom report mother/caregiver twice-daily axillary temperature measurement 14 day post administration vaccine/placebo . Stool specimen collect administration vaccine/placebo , twice week follow administration ( day 3 7 ) , day 28 administration evaluate vaccine virus shed . Weekly record adverse event also do next 2 week i.e . day 21 28 post administration vaccine/placebo . If gastrointestinal sign symptom occur time 4 week observation period , attempt make collect stool sample daily ( maximum 2 per day ) illness persist , examine presence vaccine strain . Immunogenicity determine analysis serum obtain immunization 28 day immunization change titer rotavirus antibody .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infant Consent available Evidence renal , cardiovascular , liver reticuloendothelial , neurological , gastrointestinal , hematologic , rheumatologic immunologic disease</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>rotavirus</keyword>
	<keyword>vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>infant</keyword>
</DOC>